The aim of our study was to evaluate whether any association exists between metabolic syndrome (MS) and ACE I/D and AGT M235T gene polymorphisms in Hungarians as an example of European Caucasian population. Study subjects of our cross-sectional study were recruited from the Hungarian General Practitioners' Morbidity Sentinel Stations Program. The study population (n = 1762) approximates very well the age and sex distribution of the general Hungarian population. MS was defined according to the latest diagnostic criteria proposed by the International Diabetes Federation. The frequency of DD genotype (31.36% vs. 25.42%, p = 0.006) and the frequency of D allele (0.56 vs. 0.51, p = 0.006) were significantly higher in the metabolic group than in the non-metabolic group. The distribution of the AGT M235T polymorphism was similar in each group investigated. Association was shown in the case of patients in whom central obesity was combined with elevated TG and low HDL cholesterol level (p = 0.024 and p = 0.022). It suggests that ACE I/D polymorphism is likely to be involved in lipid metabolism.
Introduction
The term 'metabolic syndrome' (MS) was introduced about two decades ago to identify a cluster of clinical symptoms such as hypertension, hyperglycaemia, central obesity with abdominal fat deposition and dyslipidaemia, particularly high triglyceride (TG) level and low high-density lipoprotein concentration. 1 Many health authorities (World Health Organisation, National Cholesterol Education Program, American Association of Clinical Endocrinologists and International Diabetes Federation) have provided diagnostic criteria to identify patients with metabolic syndrome. The most widely used are the National Cholesterol Education Program Adult Treatment Panel III (ATP III) definition and the International Diabetes Federation (IDF) criteria. According to ATP III metabolic syndrome exists when three or more of the risk determinants are present: fasting plasma glucose ≥ 6.1 mmol/l, blood pressure ≥ 130/85 mmHg, triglyceride ≥ 1.7 mmol/l, high-density lipoprotein cholesterol < 1.0 mmol/l in males and < 1.3 mmol/l in females; waist circumference > 102 cm in males, > 88 cm in females. 2 The IDF has recently established a consensus definition of metabolic syndrome: central obesity (waist circumference ≥ 94 cm for males and ≥ 80 cm for females) plus any two of the following abnormalities: triglycerides > 1.7 mmol/l or specific drug treatment for this abnormality, HDL-cholesterol < 1.03 mmol/l in males and < 1.29 mmol/l in females or specific treatment for this lipid abnormality, systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 80 mmHg or antihypertensive therapy and fasting plasma glucose level > 5.6 mmol/l or previously diagnosed type 2 diabetes mellitus. 3 Though various current criteria of MS differ in the details, studies performed in previous years showed that MS is a highly prevalent disorder throughout developed countries. 4, 5 According to the NHANES III survey based on ATP III definition the prevalence of MS in the US ranges between 15% and 25% in adults, increases with age both in males and females and reaches almost 45% for subjects aged above 60 years. 6 In Hungary, using ATP III criteria, the prevalence of MS among males and females in the age groups of 20-34, 35-54 and 55-69 years is 12%, 6% and 30%, and 26%, 42 % and 43%, respectively. 7 These results are very similar to prevalence data measured in other developed countries. 6, 8, 9 The co-incidence of the above mentioned cardiovascular risk factors in complex metabolic failure worsens the life expectancies of affected people. A recent meta-analysis provided evidence that MS is associated with increased risk of diabetes, cardiovascular disease and all-cause mortality. 10 It is well known that MS has a complex pathogenesis in which interactions are involved between certain susceptibility genes and several environmental exposures, including smoking, physical inactivity, and a high calorie diet rich in saturated fat, trans-fatty acids and refined sugars. The genetic background of MS is strongly suggested by the familiar aggregation, the high concordance rates between monozygotic twins and difference in prevalence among various ethnic groups. 11 Siblings of family members with type 2 diabetes mellitus are up to four times more likely to develop type 2 diabetes mellitus than in the general population. Furthermore genome scans have identified various chromosomal regions with strong linkage to metabolic syndrome. 12, 13 In the complex pathophysiology of MS the most important alterations which are inevitable features of metabolic failure are: changed cell insulin sensitivity, metabolic failure of adipocytes, failure of lipid metabolism, increased activity of the sympatic nervous system, microangiopathy and disturbances of the hypothalamus-hypophysis-adrenal axis. 14 Consequently the metabolic pathways which are involved in the development of MS are exceedingly diverse so there are plenty of candidate genes that may be implicated in the pathogenesis of MS. [15] [16] [17] [18] [19] [20] [21] The renin-angiotensin system (RAS) is an important regulator of renal electrolyte homeostasis and blood pressure, and it is also involved in the pathological changes in organ damage through modulation of gene expression, growth, fibrosis, and inflammatory response. 22, 23 The RAS may also be involved in the development of atherosclerosis and insulin resistance because ACE inhibitor therapy reduces the prevalence of both of these disorders. 24 Two RAS polymorphisms have been extensively described in the literature: angiotensinconverting enzyme (ACE) insertion/deletion (I/D) and angiotensinogen (AGT) M235T. The deletion allele of ACE gene and 235T variant of the AGT gene have been associated with higher blood pressure levels and found more often in hypertensive than normotensive. 18, 19, [25] [26] [27] [28] Concerning the effect of these polymorphisms on the development of MS contradictory findings were reported. Studies based on Asian and Hispanic populations showed significant association between ACE I/D polymorphism and MS 18, 19, 28 while other studies on Brazilian, Slovak and
Greek population groups reported no effect on MS development. 18, 19, 27, 29, 30 The aim of our present study was to define the frequency of ACE I/D, AGT M235T gene polymorphisms and answer the question whether association exists between these polymorphisms and MS and to assess whether these polymorphisms correlate with metabolic variables in a representative sample of Hungarians. Our results show that ACE I/D polymorphism has an effect on the development of MS, suggesting that it is decisive not only in the Asian but also in -at least certain -European populations.
Materials and methods

Subjects
The Hungarian General Practitioners' Morbidity Sentinel Stations Program (HGPMSSP) was established in 1998 by the School of Public Health, University of Debrecen and the National Public Health and Medical Officer Service in order to monitor the prevalence and incidence of chronic noncommunicable diseases of great public health importance. 31 In the Hungarian population recently a cross-sectional study was performed based on this Sentinel Stations Program to define the prevalence of metabolic syndrome among Hungarians. 7 In the source-population of the study all 20-69 year old Hungarian citizens who were registered with the 59 general practitioners of the eight participant counties (Baranya, Bács-Kiskun, Hajdú-Bihar, Heves, Győr-Moson-Sopron, Komárom-Esztergom, Szabolcs-Szatmár-Bereg and Zala) were included. The counties were selected in such a way to represent both the eastern and the western part of the country and the planned sample size was 2000 people. It makes it possible to detect with a 20-25% divergence the frequency of the pathologic HDL-cholesterol level estimated to be the less frequent alteration among MS criteria indicators on the basis of earlier surveys carried out in the Hungarian adult (aged between 20 and 69 years) population. 32 The study population representing the Hungarian adult population on the basis of geographic, age and sex distribution was chosen from the source-population by coincidence. The sampling frame of the survey was formed by volunteers who do not live in social institutions, are aged between 20 and 69 years (based on data on 31 December 2005), and part of the eight participating counties' practice. The general practitioners precluded the sick living in institutions (social services etc) prior to the sampling. As the first step of the multi-stage sampling we defined the participating counties' population sample sizes on the basis of age and sex distribution. As the second step we defined the practice-specific sample sizes in a given county on the basis of the participating practices' age and sex distribution. As the third step we chose from the source-population 2006 persons by concentric systematic random sampling.
Data collection
The general practitioners collected data on demographic characteristics (age and sex), anthropometric parameters (body weight, height, waist circumference) and performed complete physical examinations and collected blood for laboratory testing to define the levels of blood components taken into consideration for the diagnosis of MS. Triglyceride, HDL-cholesterol and glucose levels were determined from sera isolated from native venous blood samples collected after overnight fasting. Blood samples were also collected in EDTA anticoagulant tubes for DNA analysis. Standard instruments were provided for GPs to measure waist circumference (circumferential waist measuring device) and blood pressure (calibrated mercury sphygmomanometer) and they were instructed to follow standard protocols.
MS was defined according to the latest and widely used diagnostic criteria proposed by the IDF. The study participants were first divided into two groups: with MS (MS+) and without MS (MS-). The MS+ group was classified into subgroups on the basis of the combination of different pathological parameters meeting MS criteria.
The study protocol was approved by the Ethic Committee of the University of Debrecen and informed consent was obtained from all participants.
DNA extraction and genotyping
DNA was extracted from peripheral blood samples of the subjects using MagNA Pure LC DNA Isolation Kit -Large Volume (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions. PCR and genotyping with melting curve analysis were performed by LightCycler real time PCR system (Roche Diagnostics GmbH, Mannheim, Germany) at a final volume of 20 μl using primers and LC Red 640 and fluorescein labelled oligonucleotides. The details of PCR-based protocols used to identify ACE I/D and AGT M235T polymorphisms have been described previously. 33, 34 The melting curves were genotyped by two investigators, blind to subjects' metabolic phenotype.
Statistical analysis
Normally distributed parameters are presented as means (± SD) for different groups and subgroups in both genders and were compared with Student's t test. Logarithmic transformation of BMI and reciprocal square root transformation of average systolic blood pressure were used to achieve normal distribution. The overall allele frequencies of the study populations are calculated from the overall genotype distributions according to the gene counting method. The Hardy-Weinberg equilibrium was estimated by comparing observed and expected genotype frequencies. Statistical differences in genotype distribution and also allele frequencies among study groups/subgroups were assessed by the χ 2 test. A multiple logistic regression model was used to estimate the effect of genotypes on the likelihood of MS and its different components. A value of p < 0.05 was considered statistically significant. STATA software 9.2 (Collage Station, Texas) was used to perform statistical analysis.
Results
One thousand eight hundred and nineteen persons (91%) from the invited population volunteered to participate in the study; 1762 blood samples were technically suitable for DNA isolation and genotyping. Six hundred and forty-one persons had MS whereas 1121 did not meet the above-mentioned IDF criteria. Clinical and laboratory characteristics of these two groups (MS+ and MS-) are presented in table 1. The prevalence of MS in the two sex groups was slightly different (p = 0.02). Besides central obesity as the essential requirement of the MS diagnosis the most frequent finding among the metabolic components was raised blood pressure or treatment of previously diagnosed hypertension (87%); 50% (n = 320) of the patients had two and 35% (n = 224) of the patients had three metabolic abnormalities besides central obesity. All metabolic components were observed in 15% (n = 97) of the patients ( as shown in table 5 ). The most frequent component combination was central obesity, dyslipidaemia and hypertension (21%).
The frequency of AC II, ID and DD genotypes were 19.5% (n = 125), 49.1% (n = 315) and 31.4% (n = 201) in the group of patients with MS and 23.1% (n = 259), 51.5% (n = 577) and 25.4% (n = 285) in patients without MS, respectively. The frequency of DD genotype (31.36% vs. 25.42%, p = 0.006) and the frequency of D allele (0.56 vs. 0.51, p = 0.006) were significantly higher in the group of MS+ patients than in the MS-group (table 2) . The distribution of AGT M235M, M235T and T235T genotypes in the MS+ group were 27.5% (n = 176), 48.8 % (n = 313) and 23.7 % (n = 152), with 25.4% (n = 285), 51.4% (n = 576) and 23.2% (n = 260) in the MS-group, respectively. Similar distribution of AGT genotypes was found in the two study groups (data not shown).
The overall allele frequencies in the sample representative for the Hungarian adult population were 0.51 and 0.49 for AGT allele M235 and allele 235T, and 0.47 and 0.53 for ACE allele I and allele D, respectively. Genotype frequencies in study groups were all in accordance with the Hardy-Weinberg equilibrium and similar to those published in the literature for Caucasians. The genotype frequencies were also assessed in males and females. The genotype and allele distributions were found not significantly different between males and females (data not shown). Table 3 shows the result of the logistic regression model, which revealed association of DD genotype with MS (odds ratio [OR] = 1.46, 95% confidence interval [CI] = 1.10-1.93, p = 0.008). This result indicates that subjects with DD genotype compared with II genotype have 46% higher risk for developing MS. Adjustment for the confounding effect of obesity did not modify these values.
No significant relationship with any of the metabolic components and ACE genotypes was found (table 4). The prevalences of different component combinations according to different ACE genotypes are shown in table 5. Among patients with central obesity, elevated TG and low HDLcholesterol level, significant association with ACE DD genotype was shown. The DD genotype subjects in this subgroup have 2.7 times higher risk (OR: II vs. DD; 95% CI: The II genotype was considered as reference. * p = 0.008, data are crude odds ratios. II: insertion/insertion, ID: insertion/deletion, DD: deletion/deletion, n: number of individuals, HT: high blood pressure or treatment, GIT: glucose intolerance or treatment, TG: high triglyceride or treatment, HDL-C: low HDL-cholesterol or treatment.
1.14-6.31, p = 0.024) for developing MS compared with those with II genotype. Furthermore, significant association was found when dyslipidaemia was combined with high blood pressure. Both ID (OR = 1.7, 95% CI: 1.02-2.9, p = 0.038) and DD (OR = 1.9, 95% CI: 1.1-3.3, p = 0.022) genotypes increased the risk of developing MS. The AGT M235T gene polymorphism was not associated with MS as an entity or any of its components.
Discussion
We have examined the distribution ACE I/D and AGT M235T gene polymorphisms in a sample representative for the Hungarian adult population (n = 1762) consisting of 641 patients with MS according to the IDF criteria and 1121 subjects without MS in a cross-sectional study. Our study population approximates very well the age and sex distribution of Hungarian adults aged 20-69 years. Thus the allele frequencies calculated from the observed genotype distributions of this reference population can be considered representative for the Hungarian adult population. The risk allele prevalences are changing from one population to other. The 235T allele of AGT gene is the most frequent among African (0.8-0.9) and Asian populations (0.65-0.75) and less frequent among Caucasian populations (0.35-0.4). The D allele of ACE gene is the most frequent among Africans (0.6-0.7) and Caucasians (0.5-0.63) and less frequent among Asian populations (0.27-0.4). 35 The gene polymorphisms investigated in the study were selected on the basis of their previously reported associations with MS. Many studies have investigated associations between these polymorphisms and separate components of MS as well as with MS as defined on the basis of ATP III criteria. Our results are in accordance with those of some previous studies in other non-Caucasian populations. Alvarez-Aguilar et al. reported that the DD genotype of ACE gene increases susceptibility to MS in Mexican population. 28 Lee and Tsai have showed that DD genotype confers an increased risk factor for MS with dyslipidaemia and albuminuria in the Chinese population. 18 In contrast, no significant associations between ACE gene I/D polymorphism and MS were found in a Brazilian population with European ancestries. 27 On the basis of the contradictory findings it was supported that the allele frequency of ACE gene varies according to ethnic group. Our observation that D allele is associated with MS confirmed that ACE I/D polymorphism has an effect on the development of MS also in the European population. The effect of the AGT M235T polymorphism on metabolism has also been studied. Pollex et al. investigated the possible genetic determinants of metabolic syndrome in aboriginal Caucasians. 36 They have chosen only polymorphisms that were previously found to be associated with individual components of MS in this population but they have not found any association between AGT M235T polymorphism and MS. 36 Thomas et al. also investigated this AGT polymorphism for a possible role in modulating various components of the metabolic syndrome in Chinese subjects. There was limited evidence to suggest that the AGT M235T polymorphism may be associated with certain disturbances in lipid metabolism. 19 Both the ACE D allele and AGT M235T polymorphism were reported formerly to influence susceptibility to hypertension. 37, 38 Therefore we expected an association between the polymorphisms and elevated blood pressure but our investigation failed to detect any significant association of the polymorphism with this disorder.
Dyslipidaemia in MS is characterised by high triglyceride levels and/or low high-density lipoprotein concentration. Subjects with DD and ID genotype were found in this study to have a significantly higher prevalence of dyslipidaemia. These results suggest that the renin-angiotensin system may play a role in lipid metabolism and the role in lipid metabolism is more prevalent than its effect on regulation of blood pressure. Although it is an unexpected finding, it can be interpreted as genes coding all components of the RAS are found to be expressed in adipose tissue, 39 which may have multiple functions including prostaglandin production and adipose tissue lipolysis. 36, 37 ACE inhibitor therapy has been shown to induce improvements in atherosclerosis and insulin resistance, by this means lowering the risk of developing diabetes, 40 which suggests that the RAS pathway has significant impact not only on vascular functions but also on metabolic traits, and the activation of RAS may promote the development of dyslipidaemia and diabetes.
Among other RAS pathway components AGT is synthesised not only in the liver but also in adipose tissue and it is known to regulate the growth of adipose tissue. AGT T235T gene polymorphism is linked to visceral obesity and insulin resistance in Japanese females, and carrying this genotype confers increased risk for obesity related diseases in Japanese women. 41 Anther study concluded that AGT may play a role in insulin resistance. 42 We have increased the homogeneity of study groups with MS by sub-grouping them according to clinical phenotype. This breakdown resulted in smaller sample sizes. Nevertheless some of the subgroups were large enough to make it possible to detect significant differences in genotype distribution of ACE I/D polymorphism.
Although there was no evidence that any of the RAS polymorphisms may be associated with individual components of the syndrome there was evidence that ACE I/D gene polymorphism affects the clustering of the components of metabolic syndrome. Furthermore there was consistent evidence showing ACE I/D polymorphism and dyslipidaemia including increased frequency of D allele containing genotypes in the metabolic syndrome group, where all had central obesity and dyslipidaemia combined.
Conclusions
This is the first genetic association study that shows a relationship between ACE gene I/D polymorphism and metabolic syndrome among Hungarian adults. It revealed that D allele is associated with increased susceptibility for developing MS but no association was found between AGT M235T polymorphism and metabolic syndrome. No relationship was found with any of the separate metabolic components and ACE genotypes, but in the case of patients in whom central obesity was combined with elevated TG and low HDL-cholesterol level, significant association was shown.
